GPCR Antagonism via Antibody-Mediated Rewiring of Receptor Trafficking and Degradation
Rhee, K.; Shue, L.; Adachi, A.; Osei-Owusu, J.; Zhou, D.; Cheng, A.; Baluapuri, A.; Harvey, E. P.; Adelman, K.; Skiba, M. A.; Huh, J. R.; Kruse, A. C.; Zhou, X.
Show abstract
G-protein coupled receptors (GPCRs) represent one of the most important yet incompletely targeted classes of therapeutic proteins. Here, we report a novel strategy for functional GPCR antagonism through antibody-mediated endocytosis and lysosomal degradation. Our engineered bispecific antibodies, termed GPCR-TfR1 Targeting Chimeras (GTACs), achieve potent and selective downregulation of various GPCRs, including RXFP1 and CCR6, critical cancer and immune drug targets that are difficult to antagonize with conventional approaches. GTACs led to complete inhibition of receptor activity with over 100-fold greater potency than conventional antibody antagonists. Using four-color imaging, we elucidated the trafficking mechanism of both the target protein and TfR1 in living cells. The GTAC platform enables robust antagonism of signaling across diverse GPCR families and establishes induced endocytosis and lysosomal trafficking as a fundamentally new paradigm for therapeutic GPCR modulation.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Membrane curvature association of amphipathic helix 8 drives constitutive GPCR endocytosis 96%
- GABARAP membrane conjugation sequesters the FLCN-FNIP tumor suppressor complex to activate TFEB and lysosomal biogenesis 96%
- A new universal chimeric-antigen receptor (CAR)- fragment antibody binder (FAB) split system for cancer immunotherapy 95%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.